Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296229 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
A NA study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT02296229: Active NA study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.
NCT02296229 is a NA study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 220 participants, above the 99-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (122% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02296229, a NA study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Studying quality of life in patients undergoing stereotactic body radiation therapy may help identify the long-term effects of treatment on patients with prostate cancer.
Primary Outcome
Biochemical progression is defined as rising PSA profile of \> 2 ng/mL above post-SBRT nadir.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- RADIATION stereotactic body radiation therapy
- OTHER quality-of-life assessment
- DRUG androgen deprivation therapy
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2014-01-27 |
| Est. Completion | 2027-01-27 |
| Phase | NA |
What the registry record for NCT02296229 still lists
NCT02296229 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 99-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (122% higher).
The record links to 2 conditions, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02296229 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02296229 about?
NCT02296229 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer". This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of rad...
What is the current status of trial NCT02296229?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2014-01-27. Estimated completion is 2027-01-27.
What conditions does trial NCT02296229 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer.
What interventions are being tested in trial NCT02296229?
The interventions under investigation include: laboratory biomarker analysis (OTHER), stereotactic body radiation therapy (RADIATION), quality-of-life assessment (OTHER), androgen deprivation therapy (DRUG).
Who is sponsoring clinical trial NCT02296229?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296229 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02296229's enrollment target sits among peer trials
220 2nd of 21 the highest of 21 other Adenocarcinoma of the Prostate trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Prostate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
ACTIVE NOT RECRUITING · NA
-
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer
COMPLETED · NA
-
Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping
COMPLETED · NA
-
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
COMPLETED · NA
-
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
COMPLETED · NA
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI